| Date:2021-12-1 | |
|--|-------------|
| Your Name: Jun Gong | |
| Manuscript Title: LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer | progression |
| by targeting the miR-629-5p/TXNIP axis_ | |
| Manuscript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | X None | |
|-----|---|--------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| 7 | Support for attending | V Name | |
| ′ | meetings and/or travel | X None | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | X None | |
| O | pending | X Notic | |
| | benom 8 | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | _ X None | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the fol | lowing box: |
| Г | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |

| Date: | 2021-12-1 |
|------------------|--|
| Your Name | :Lei Ma |
| Manuscript | : Title:_ LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression |
| by targeting | g the miR-629-5p/TXNIP axis_ |
| Manuscript | number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| 1 | All augus aut fau tha pusasut | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, | X None | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | X None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | X None | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |
| | | | |

| | | ı | |
|-----|---|---|--|
| | | | |
| 5 | lectures, presentations, | X None | |
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| _ | | | |
| 7 | Support for attending | X None | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | X None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| 11 | Stock of Stock Options | XNOTIE | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| 12 | materials, drugs, medical | _ANone | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| Ple | ease summarize the above of | onflict of interest in the following box: | |
| | None. | | |
| | | | |
| | | | |

| Date:_ | 202 | 1-12-1 |
|---------|-------------|--|
| Your N | Name: | Chunlei Peng |
| Manus | script Titl | e:_ LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression |
| by targ | geting the | e miR-629-5p/TXNIP axis_ |
| Manus | script nui | mber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | X None | | | |
|-----|------------------------------|---|--|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | X None | | | |
| | testimony | | | | |
| | , | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | x none | | | |
| | meetings and/or traver | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | X None | | | |
| 10 | in other board, society, | XNone | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | | | | |
| | | | | | |
| 12 | Descipt of aguing ant | V News | | | |
| 12 | Receipt of equipment, | _ X None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| 12 | services | V | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Ple | ease summarize the above c | onflict of interest in the following box: | | | |
| | | | | | |
| | None. | | | | |
| | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |
| | | | |
| | | | |

| Date: | 2021-12-1 | |
|----------|---|----|
| Your Na | ame: <u>Jianhua Liu</u> | |
| Manusc | cript Title: LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression | on |
| by targe | eting the miR-629-5p/TXNIP axis_ | |
| Manusc | cript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| _ | Devenous on beautiful | V 1 | | |
|-----|--|-----------------|--|--|
| 5 | Payment or honoraria for | XNone | | |
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| _ | educational events | V | | |
| 6 | Payment for expert | XNone | | |
| | testimony | | | |
| | | | | |
| 7 | Support for attending | X None | | |
| | meetings and/or travel | | | |
| | | | | |
| | | | | |
| | | | | |
| 8 | Patents planned, issued or | X None | | |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | X None | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | X None | | |
| | in other board, society, | | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | X None | | |
| | | | | |
| | | | | |
| 12 | Receipt of equipment, | _ X None | | |
| | materials, drugs, medical | | | |
| | writing, gifts or other | | | |
| 4.5 | services | | | |
| 13 | Other financial or non- | XNone | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| | Disease supervises the charge conflict of interest in the fall suring beau | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | |
| | | | | |
| | None. | | | |
| | | | | |
| | | | | |